Kyushu University [Kentaro TANAKA (Associate Professor) Faculty of Medical Sciences, Department of Clinical Medicine]

Kentaro TANAKA

Last modified date：2023.06.29

Associate Professor / Internal Medicine
Department of Clinical Medicine
Faculty of Medical Sciences

2 Academic Activities

Graduate School

Undergraduate School

Department of Medicine
School of Medicine

Other Organization

Respiratory Medicine

Administration Post

Other

E-Mail　*Since the e-mail address is not displayed in Internet Explorer, please use another web browser:Google Chrome, safari.

Homepage

Phone

092-642-5378

Academic Degree

MD, PhD

Country of degree conferring institution (Overseas)

Field of Specialization

Medical Oncology, Respiratory Medicine, Immunology

Total Priod of education and research career in the foreign country

04years03months

Research

Research Interests

Role of MAPK signaling in regulatory mechanisms of immune checkpoint molecules.
keyword : MAP kinase, immune checkpoint molecule, IL-1beta, IFN-gamma
2022.01～2026.03.
Development of novel immunotherapies to overcome resistance to immune checkpoint inhibitors.
keyword : advanced non-small cell lung cancer, resistance, immunotherapy
2016.04～2023.03.
Function of Hippo pathways in non-small cell lung cancer
keyword : Hippo pathway, non-small cell lung cancer
2017.04～2024.03.
Development of biomarkers in the treatment of immune checkpoint inhibitors
keyword : biomarker, immune checkpoint inhibitor, T lymphocyte, metabolite
2017.09～2024.03.
basic research and development of new treatment in small-cell lung cancer
keyword : advanced small cell lung cancer, clinical trials
2017.09～2025.03.
Regulation of immune system in tumor cells by cytokines in the tumor microenvironment
keyword : tumor cells, immune checkpoint, tumor microenvironment, cytokine, macrophage
2020.01～2024.12.
Clinical development of novel treatment for advanced EGFR-mutation positive non-small cell lung cancer
keyword : lung cancer, novel treatment, clinical trials
2017.10～2021.12.

Academic Activities

Papers

Show All Papers >>

1.	Asahina H, Tanaka K, Morita S, Maemondo M, Seike M, Okamoto I, Oizumi S, Kagamu H, Takahashi K, Kikuchi T, Isobe T, Sugio K, Kobayashi K, A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801) , Clinical Lung Cancer, 2021.03.
2.	Ando N, Tanaka K, Otsubo K, Toyokawa G, Ikematsu Y, Ide M, Yoneshima Y, Iwama E, Inoue H, Ijichi K, Tagawa T, Nakanishi Y, Okamoto I, Association of MOB1 Expression with Poor Disease-Free Survival in Individuals with Non–Small Cell Lung Cancer, Thoracic Cancer, 2020.11.
3.	Ikematsu Y, Tanaka K, Toyokawa G, Ijichi K, Ando N, Yoneshima Y, Iwama E, Inoue H, Tagawa T, Nakanishi Y, Okamoto I, NEUROD1 is highly expressed in extensive-stage small cell lung cancer and promotes tumor cell migration., Lung Cancer , 2020.08.
4.	Yanagihara T, Tanaka K, Matsumoto K, A measuring method for occupancy of immune checkpoint inhibitors in the cell surface, Biochemical and Biophysical Research Communications, 2020.06.

Presentations

Show All Presentations >>

1.	Kentaro TANAKA, 「Next-generation TKI」, World Conference on Lung Cancer, 2018.10.

Educational

Other Educational Activities

Unauthorized reprint of the contents of this database is prohibited.